HLA-C and cancer: The recognition of antigen epitopes presented by major histocompatibility complex (MHC) molecules by T cell receptor (TCR) binding is the crucial initial step in adaptive immunity [1], also key to various cancer immunotherapies such as checkpoint inhibitors [2], cancer vaccines [3] and TCR-based agents [4, 5].